Member Info for olderbutwiser

I do not think CPI selling means anything - they will not have inside info, are a government agency and can sell at any price and still gain.
It may wobble a few traders and allow a bit of MM shenanagins.
But I am just ignoring it.

We are assuming that AZN is the originator- IT MAY WELL NOT BE – but bulletin boards and social media will create links and a story from the smallest of whispers.
We are building it up and reading into it all sorts of things – why should it scupper anything? - effectively nothing has been said.
Nuformix BOD appear to hold their cards pretty close and I certainly doubt that Wallbrook are party to who the originator is – If you were CEO would you tell a PR company anything you didn’t want spread around!
However it was one of the strangest combination of companies and garbled information about Nuformix in any investment video I have ever seen.

Soupdragon78 - I believe it was your research that first identified AZN as the potential originator and which was then spread around the bulletin boards - so did you want to scupper any talks? LOL

Alistair Riddell becomes Exec Chairman.
004 second patent filed - based upon good research data.
A good week - pity about the sp - but that will follow.
Looking forward to next week now.
Have a good weekend all

I asked this very question earlier in the year and had a reply that said the following:
'Subject to a favourable research outcome and once the (second) patent is filed they are able to approach the originator'.
So presumably they are able to start now or have started preliminary discussions already - dependent upon the formal date of filing the patent.

I agree Chablard which is why I have bought more this morning.
I think this will do very well once the impatient traders move on.
GLA

This is excellent news which the market will (eventually) wake up to.
The 004 patent news provides the following:
• 10 year licensing extension on existing blockbuster oncology drug
• Improves the drug by reducing side effects
• Because of the reduced side effects the drug could now be available to be used in other therapeutic areas
• I has apparently already shown promise in fibrosis use
Now the second patent is submitted Nuformix will formally approach the originator and start discussion/ negotiations.

Then 002 news to come shortly.

I think this could well be another SAR

In the 22 mar 2021 RNS the following was stated:
'NXP004 (undisclosed drug) - Oncology
The Company has discovered novel forms of an undisclosed marketed oncology drug that has significant sales (more than £1 billion per annum in 2020) and is showing further growth. The Company has filed one patent application on these novel forms and is currently conducting further research on other new forms and their properties. Should the further research warrant it, the Company may file an additional patent application. In addition, the Company is evaluating the potential advantages of the new forms that have been discovered. If the patents on these new forms are granted there is potential for patent expiry to extend to 2040/2041. While there is literature data and preliminary preclinical data generated by the Company providing evidence for this drug's potential activity in fibrosis, it is the Company's strategy that in order to derive most value from the NXP004 asset, the opportunities in oncology should be exploited as a priority.
Should the further research be positive, there are two potential options for licensing the Company's IP to generate value from NXP004:
· license to the originator of the marketed drug to potentially extend its patent protection, thus potentially adding significant value for the originator; or
· license to generic companies to potentially allow commercialisation of a generic alternative to the marketed drug.'

The following was stated in the 22 Dec 2020 RNS
'NXP004 uses Nuformix proprietary technology applied to the active drug of a multi-billion-dollar product currently marketed for oncology indications. Despite the commercial success of the marketed product, side-effects pose a significant challenge to its existing use and extension into new indications, that could also benefit from its mechanism of action. We are currently evaluating new IP that could overcome some of the challenges posed by the originator's formulation.
Additionally, in August, the Group reported results from a pre-clinical pilot study evaluating the anti-fibrotic and anti-inflammatory effects of NXP004 against standard of care, a therapeutic area not currently exploited by the originator of the drug. We will confirm next steps in Q1 2021.'
So much potential with much reduced side effects and therefore enabling new therapeutic areas to be commercialised for the existing major pharma.

Would be nice to see Nuformix website updated with Riddell move to Exec Chairmen and this latest news on or are they waiting for imminent 002 news to update them all at once?
Once the one day wonder investors have cleared off this should rise over the next days and weeks as the value investors see the huge potential here.

No wonder Alistair Riddell was happy to become Exec Chairmen - he knew that good news was coming on 004 and presumably 002 too.

Brilliant news.
Now that the new patent has been filed Nuformix will now initiate discussions with the billion pound a year pharma company.
Things could speed up from here.

Why is there an assumption that Anne finishes on same day that Riddell becomes Exec Chairman?
The RNS on 21st July stated the following
'Anne will continue in her current position for the next six months and has committed to assist the Company with an orderly transition for that period'
That would mean that Anne leaves on the 21st January, or thereabouts.
Riddell becoming Exec Chairmen was always a strong possibility and could have been formalised any time before Anne leaves, so I do not see the rationale for saying Anne will leave on same date..

https://www.bbc.co.uk/news/business-59044820

OR it might mean that NXP002 would be required/ much better as the basis for lymphatic delivery too - if indeed that is a future option.

I believe that one of the major problems with using 'vanilla tranilast' was its extremely poor solubility - which Nuformix's NXP002 overcomes.
Good solubility is usually a key aspect for most drug delivery mechanisms and presumably is even if it is delivered via the lymphatic system.

It certainly is a funny old world - when the most persistently vocal shareholders are so negative on an almost daily basis and then bleat about the share price being low?
Soup - what questions would you have asked that the BOD would have given an answer to - and why didn't you go to the AGM to ask them or send in your questions as requested?
Just an observation.

Excellent post Soup - really interesting stuff.
Oxilio aspect is particularly interesting -in conjunction with the comments 'TRx has created a business model offering immense speed of product development' and “The exciting aspect for us is that (Oxilio) clinical trials are an opportunity to treat patients and it’s possible that we may be able to treat patients in late 2022 or early 2023. For a technology that’s so disruptive, that’s incredibly fast.”
So stage payments from Oxilio to Nuformix may be sooner than previously thought.
I am just wondering whether their technology is relevant/ advantageous to NXP002 or NXP004?
Things are moving fast in all sorts of directions!
Hopefully studu results very soon.
GLA

You may be right Soup - so that is something to be aware of , for others like me, who are not paid up members of LSE site - do not rely on LSE trade data after about 15.00 it will probably not be complete.
As you say Goup - 'strange'.
It seemed to spook a few into a short term sell-off. So was it an innocent error? or something else ? Usually when a trade correction is shown (-ve)the two trades have the same price !

It is not just NFX shares they do not show all trades for - I have checked other stocks and London South East has not shown many trades from late afternoon which The London Stock Exchange website does show.
This can be very misleading - often large trades will be shown as after 17.00 hours .